Risk of severe respiratory syncytial virus disease, identification of high risk infants and recommendations for prophylaxis with palivizumab.

Authors :: Meissner HC
Rennels MB
Pickering LK
Hall CB
Source :: The Pediatric infectious disease journal [Pediatr Infect Dis J] 2004 Mar; Vol. 23 (3), pp. 284-5.
Publication Year :: 2004

Subjects :: Antibodies, Monoclonal, Humanized
Antiviral Agents administration & dosage
Drug Administration Schedule
Hospitalization statistics & numerical data
Hospitalization trends
Humans
Infant, Newborn
Infant, Premature
Intensive Care Units, Neonatal
Palivizumab
Practice Guidelines as Topic
Primary Prevention methods
Respiratory Syncytial Virus Infections drug therapy
Risk Assessment
Antibodies, Monoclonal administration & dosage
Respiratory Syncytial Virus Infections prevention & control

Full Text Access

Tools